MX2017014547A - Secuencias de uricasa mejoradas y metodos de tratamiento. - Google Patents

Secuencias de uricasa mejoradas y metodos de tratamiento.

Info

Publication number
MX2017014547A
MX2017014547A MX2017014547A MX2017014547A MX2017014547A MX 2017014547 A MX2017014547 A MX 2017014547A MX 2017014547 A MX2017014547 A MX 2017014547A MX 2017014547 A MX2017014547 A MX 2017014547A MX 2017014547 A MX2017014547 A MX 2017014547A
Authority
MX
Mexico
Prior art keywords
methods
treatment
uricase sequences
improved
improved uricase
Prior art date
Application number
MX2017014547A
Other languages
English (en)
Inventor
Baca Manuel
C Nyborg Andrew
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2017014547A publication Critical patent/MX2017014547A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Se describen secuencias de uricasa mejoradas que tienen efectos beneficiosos y métodos para tratar a pacientes que padecen hiperuricemia.
MX2017014547A 2015-05-15 2016-05-13 Secuencias de uricasa mejoradas y metodos de tratamiento. MX2017014547A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562162280P 2015-05-15 2015-05-15
PCT/US2016/032415 WO2016187026A1 (en) 2015-05-15 2016-05-13 Improved uricase sequences and methods of treatment

Publications (1)

Publication Number Publication Date
MX2017014547A true MX2017014547A (es) 2018-03-15

Family

ID=57320301

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014547A MX2017014547A (es) 2015-05-15 2016-05-13 Secuencias de uricasa mejoradas y metodos de tratamiento.

Country Status (18)

Country Link
US (3) US11098289B2 (es)
EP (1) EP3294322A4 (es)
JP (2) JP2018515101A (es)
KR (1) KR20180002828A (es)
CN (1) CN107614007B (es)
AU (2) AU2016265677B2 (es)
BR (1) BR112017024212A2 (es)
CA (1) CA2984926A1 (es)
CL (1) CL2017002774A1 (es)
CO (1) CO2017012454A2 (es)
HK (1) HK1252542A1 (es)
IL (1) IL255403A0 (es)
MX (1) MX2017014547A (es)
MY (1) MY190411A (es)
RU (1) RU2752497C2 (es)
SG (2) SG10201910522TA (es)
WO (1) WO2016187026A1 (es)
ZA (1) ZA201708507B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11098289B2 (en) 2015-05-15 2021-08-24 Medimmune, Llc Uricase sequences and methods of treatment
CN106554948B (zh) * 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
CN112410313A (zh) * 2019-08-20 2021-02-26 中国科学院上海药物研究所 一种高热稳定性尿酸酶及其应用
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
WO2021083278A1 (en) * 2019-10-29 2021-05-06 Westlake Therapeutics (Hangzhou) Co. Limited Engineering red blood cells for treating gout and hyperuricemia diseases
US20230374471A1 (en) * 2020-10-13 2023-11-23 University Of Florida Research Foundation, Incorporated Self-assembling uricase fusion peptides
KR20230110281A (ko) 2020-11-03 2023-07-21 프로탈릭스 리미티드 변형된 유리카제(uricase) 및 이의 용도
CN115197923A (zh) * 2021-04-09 2022-10-18 上海君实生物医药科技股份有限公司 尿酸酶、其药物组合物及其用途
KR20240049312A (ko) * 2021-07-08 2024-04-16 주식회사 프로앱텍 Arthrobacter globiformis 유래 요산산화효소-알부민 접합체, 그 제조방법 및 그 용도
WO2023048505A1 (ko) * 2021-09-23 2023-03-30 주식회사 프로앱텍 Apn 그룹을 포함하는 링커 및 이를 이용하여 제조된 기능성 폴리펩티드 변이체-알부민 컨쥬게이트
WO2023064732A1 (en) * 2021-10-15 2023-04-20 Georgia State University Research Foundation, Inc. Delivery of therapeutic recombinant uricase using nanoparticles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09154581A (ja) * 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
JP5183836B2 (ja) 1998-08-06 2013-04-17 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Ｐｅｇ−尿酸酸化酵素結合体およびその使用
EP2158923B1 (en) * 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PT1100880E (pt) 1998-08-06 2011-01-13 Univ Duke Urato-oxidase
BR122013003013B8 (pt) * 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
RU2435847C2 (ru) * 2005-04-11 2011-12-10 Савиент Фармасьютикалз, Инк. Вариантная форма урат-оксидазы и ее использование
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
PL3321359T3 (pl) * 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Wariantowe postacie oksydazy moczanowej i ich zastosowanie
US20130305398A1 (en) * 2012-02-16 2013-11-14 Marie Coffin Genes and uses for plant enhacement
ES2716864T3 (es) 2007-06-06 2019-06-17 Monsanto Technology Llc Genes y usos para la mejora de plantas
KR101861547B1 (ko) 2009-06-25 2018-07-02 크레알타 파마슈티칼스 엘엘씨 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체­매개 상실을 예측하는 방법 및 키트
CN103184209B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
US11098289B2 (en) 2015-05-15 2021-08-24 Medimmune, Llc Uricase sequences and methods of treatment

Also Published As

Publication number Publication date
RU2752497C2 (ru) 2021-07-28
US20210254024A1 (en) 2021-08-19
CL2017002774A1 (es) 2018-04-06
CN107614007B (zh) 2022-03-25
AU2016265677A1 (en) 2018-01-04
AU2016265677B2 (en) 2021-12-09
SG11201708759YA (en) 2017-11-29
BR112017024212A2 (pt) 2018-07-17
WO2016187026A1 (en) 2016-11-24
JP2021184733A (ja) 2021-12-09
MY190411A (en) 2022-04-21
CO2017012454A2 (es) 2018-04-30
CA2984926A1 (en) 2016-11-24
KR20180002828A (ko) 2018-01-08
SG10201910522TA (en) 2020-01-30
HK1252542A1 (zh) 2019-05-31
US10883087B2 (en) 2021-01-05
US20190048327A1 (en) 2019-02-14
EP3294322A4 (en) 2018-12-12
RU2017143580A (ru) 2019-06-17
US20180258406A1 (en) 2018-09-13
RU2017143580A3 (es) 2019-12-16
EP3294322A1 (en) 2018-03-21
US11098289B2 (en) 2021-08-24
IL255403A0 (en) 2017-12-31
AU2022200104A1 (en) 2022-02-03
ZA201708507B (en) 2018-11-28
JP2018515101A (ja) 2018-06-14
CN107614007A (zh) 2018-01-19

Similar Documents

Publication Publication Date Title
MY190411A (en) Improved uricase sequences and methods of treatment
IL273824A (en) Methods of using ehmt2 inhibitors in the treatment or prevention of blood disorders
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
MX2017010150A (es) Bacterias probioticas recombinantes.
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
EA201791095A1 (ru) Способ лечения рака
MX2018012230A (es) Métodos para tratar enfermedades oculares.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
ZA201703467B (en) Methods of treating ocular conditions
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
GB202015959D0 (en) Treatment of diseases involving NAD
IL268111A (en) Methods of treating pain
IL290983A (en) Treatment methods
GB201918853D0 (en) Methods of treatment
GB201900942D0 (en) Methods of treatment
GB202118006D0 (en) Methods of treatment
GB202118007D0 (en) Methods of treatment
GB202118011D0 (en) Methods of treatment
GB202108245D0 (en) Methods of treatment
GB202108242D0 (en) Methods of treatment
GB202005874D0 (en) Methods of treatment
IL287250A (en) Method of treatment
EP3813824A4 (en) MYELINIZATION STIMULATING COMPOUNDS AND METHODS OF TREATMENT